What is Biohaven's G&A?

Biohaven (BHVN) reported G&A of $26.6M in Q1 2026.

How has Biohaven's G&A changed year-over-year?

Biohaven's G&A decreased by 21.7% year-over-year, from $33.98M to $26.6M.

What is the long-term trend for Biohaven's G&A?

Over 3 years (2022 to 2025), Biohaven's G&A has grown at a -5.5% compound annual growth rate (CAGR), from $130.86M to $110.31M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Biohaven BHVN G&A

G&A at other companies

Xenon PharmaceuticalsXENE

$23.82M+25.1%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Monte Rosa Therapeutics, Inc.GLUE

$10.18M+16.9%

Vera TherapeuticsVERA

$39.12M+146%

Nurix Therapeutics, Inc.NRIX

$14.61M+25.4%

AnaptysBio, Inc.ANAB

$26.2M+85.4%

Other financials

Income statement

See full

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

See full

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

See full

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

See full

Market cap$2.25B-48.1%

Enterprise value$2.26B-46.3%

Returns & leverage

See full

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biohaven's G&A?: Biohaven (BHVN) reported G&A of $26.6M in Q1 2026.
How has Biohaven's G&A changed year-over-year?: Biohaven's G&A decreased by 21.7% year-over-year, from $33.98M to $26.6M.
What is the long-term trend for Biohaven's G&A?: Over 3 years (2022 to 2025), Biohaven's G&A has grown at a -5.5% compound annual growth rate (CAGR), from $130.86M to $110.31M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.